2018年天津中医药大学第一附属医院口服降糖药的使用情况分析
|
摘要
目的分析2018年天津中医药大学第一附属医院口服降糖药物的使用情况,为促进临床合理用药提供依据。方法应用限定日剂量(DDD)法对2018年天津中医药大学第一附属医院口服降糖药物的种类、销量、销售金额、用药频度(DDDs)、日均费用(DDC)和排序比(B/A)进行统计。结果α-糖苷酶抑制剂类药物的销售金额占所有口服降糖药的49.84%,排名第1位。双胍类药物的年销售总量居第1位。盐酸二甲双胍片、格列美脲片(2 mg)、阿卡波糖片(进口)、格列喹酮片、伏格列波糖片为DDDs排名前5的药品。阿卡波糖片的DDC明显高于其他降糖药。双胍类药物的B/A均高于1.00,伏格列波糖片、格列齐特缓释片、盐酸吡格列酮分散片、磷酸西格列汀片的B/A均为1.00,餐时血糖调节剂的B/A均低于1.00。结论天津中医药大学第一附属医院口服降糖药物的应用基本合理,仍需进一步降低患者的经济负担,促进临床合理用药。
Objective To analyze the use of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in 2018, so as to provide basis for promoting rational drug use in clinic. Methods The types, sales volume, sales amount, frequency of drug use(DDDs), defined daily cost(DDC), and drug sequence ratio(B/A) of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in 2018 were analyzed by DDD method. Results The sales amount of α-glycosidase inhibitors accounted for 49.84% of all oral hypoglycemic drugs, ranking the first. The annual sales of biguanides ranked the first. DDDs of Metformin Hydrochloride Tablets, Glimepiride Tablets(2 mg), Acarbose Tablets(import), Gliquidone Tablets and Voglibose Tablets ranked the top 5. DDC of Acarbose Tablets were significantly higher than other hypoglycemic drugs. B/A of biguanides were higher than 1.00. B/A of Voglibos Tablets, Gliclazide Sustained-release Tablets, Pioglitazone Hydrochloride Dispersible Tablets and Sitagliptin Phosphate Tablets were all 1.00. B/A of dietary glucose regulators were lower than 1.00. Conclusion The application of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine is basically reasonable. It is still necessary to further reduce the economic burden of patients and promote rational clinical use of drugs.
Objective To analyze the use of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in 2018, so as to provide basis for promoting rational drug use in clinic. Methods The types, sales volume, sales amount, frequency of drug use(DDDs), defined daily cost(DDC), and drug sequence ratio(B/A) of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine in 2018 were analyzed by DDD method. Results The sales amount of α-glycosidase inhibitors accounted for 49.84% of all oral hypoglycemic drugs, ranking the first. The annual sales of biguanides ranked the first. DDDs of Metformin Hydrochloride Tablets, Glimepiride Tablets(2 mg), Acarbose Tablets(import), Gliquidone Tablets and Voglibose Tablets ranked the top 5. DDC of Acarbose Tablets were significantly higher than other hypoglycemic drugs. B/A of biguanides were higher than 1.00. B/A of Voglibos Tablets, Gliclazide Sustained-release Tablets, Pioglitazone Hydrochloride Dispersible Tablets and Sitagliptin Phosphate Tablets were all 1.00. B/A of dietary glucose regulators were lower than 1.00. Conclusion The application of oral hypoglycemic drugs in First Teaching Hospital of Tianjin University of Traditional Chinese Medicine is basically reasonable. It is still necessary to further reduce the economic burden of patients and promote rational clinical use of drugs.
引文
[1]杨文英.中国糖尿病的流行特点及变化趋势[J].中国科学:生命科学,2018,48(8):812-819.
[2]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:655-664.
[3]董艳.2017年天津医科大学代谢病医院门诊降糖药物的使用情况分析[J].现代药物与临床,2019,34(1):229-234.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国糖尿病杂志,2018,10(1):4-67.
[5]母义明,杨文英,朱大龙,等.磺脲类药物临床应用专家共识(2016年版)[J].药品评价,2017,14(1):5-12,54.
[6]霍立双.噻唑烷二酮类药物对骨代谢影响的研究进展[D].石家庄:河北医科大学,2017.
[7]刘瑛.DPP4抑制剂治疗2型糖尿病的系统评价[D].昆明:昆明医科大学,2016.
[8]田勍,洪天配.非磺脲类胰岛素促泌剂在2型糖尿病患者血糖管理中的作用[J].中国糖尿病杂志,2016,24(2):173-176.
[9]方昱,王静至,王开明.治疗糖尿病口服降糖药新进展[J].上海医药,2019,40(1):17-19,55.
[10]赵艳雪,闫朝丽.SGLT2抑制剂治疗2型糖尿病的临床研究进展[J].医学综述,2018,24(17):3457-3461.
[2]陈新谦,金有豫,汤光.新编药物学[M].第17版.北京:人民卫生出版社,2011:655-664.
[3]董艳.2017年天津医科大学代谢病医院门诊降糖药物的使用情况分析[J].现代药物与临床,2019,34(1):229-234.
[4]中华医学会糖尿病学分会.中国2型糖尿病防治指南(2017年版)[J].中国糖尿病杂志,2018,10(1):4-67.
[5]母义明,杨文英,朱大龙,等.磺脲类药物临床应用专家共识(2016年版)[J].药品评价,2017,14(1):5-12,54.
[6]霍立双.噻唑烷二酮类药物对骨代谢影响的研究进展[D].石家庄:河北医科大学,2017.
[7]刘瑛.DPP4抑制剂治疗2型糖尿病的系统评价[D].昆明:昆明医科大学,2016.
[8]田勍,洪天配.非磺脲类胰岛素促泌剂在2型糖尿病患者血糖管理中的作用[J].中国糖尿病杂志,2016,24(2):173-176.
[9]方昱,王静至,王开明.治疗糖尿病口服降糖药新进展[J].上海医药,2019,40(1):17-19,55.
[10]赵艳雪,闫朝丽.SGLT2抑制剂治疗2型糖尿病的临床研究进展[J].医学综述,2018,24(17):3457-3461.